VTH244

VTH244 is a preclinical-stage drug candidate being developed by Verra Therapeutics. It is part of the company's proprietary platform focused on peptide-based small proteins, which are designed as modified native peptide inhibitors. While specific indications and molecular targets for VTH244 have not been publicly disclosed in detail, it belongs to a pipeline that includes treatments for chronic obstructive pulmonary disease (COPD) and post-heart attack recovery (myocardial infarction). The drug is part of a portfolio of candidates aimed at addressing inflammatory and fibrotic disease pathways identified through the company's research platform.